Anti-4-1BB [3H3]
Catalogue Number: AB01172-2.3-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | Recombinant Monoclonal |
| Alias: | CD137; 4 1BB; 41BB; Tumor necrosis factor receptor superfamily member 9; Tnfrsf9; T-cell antigen 4-1BB; Ila, Ly63; 4-1BB receptor |
| Shipping Condition: | Blue Ice |
| Unit(s): | 200 ug |
| Host name: | Mouse |
| Clone: | 3H3 |
| Isotype: | IgG2a |
| Immunogen: | This antibody was raised by immunizing Lewis rats with 4-1BB fusion proteins, composed of the extracellular domain of murine 4-1BB and the COOH region of human IgG1 . |
| Application: | ELISA, IP, Stim |
Additional Text
Uniprot ID
P20334
Gene Name
TNFRSF9
Gene ID
21942
Purification
Purified
Antibody Clonality
Recombinant Monoclonal
Storage Note
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Application Notes
The binding specificity of this antibody for 4-1BB has been confirmed in ELISA analysis using purified 4-1BB-Ig fusion protein, and immunoprecipitation analysis (Shuford et al, 1997).This antibody is able to block 4-1BBL binding to activated DO.11.10 T cells (Shuford et al, 1997). This antibody reacts with activated T cells, and can costimulate T cell proliferation induced by the 145.2C11 hamster anti- mouse CD3 mAb (Shuford et al, 1997). Equally, when administered to mice, this antibody expands innate immune cells, as well as host T cells (Lin et al, 2010). Administration of this antibody alone induced complete tumor regression in E.G7 tumor-bearing mice (Lin et al, 2010). Binding of this antibody to activated T cells in mice receiving heart allografts led to the rapid rejection of the allograft (Shuford et al, 1997).
Short Description
This chimeric mouse antibody was made using the variable domain sequences of the original Rat IgG2a format, for improved compatibility with existing reagents, assays and techniques.
AB01172-2.3 Datasheet
SUPPORT
outstanding technical support
PRODUCT
we offer a full product guarantee
DELIVERY
we offer free delivery to UK universities and non profit organisations